Five PubMed papers to open first: optogenetics for vision, an oral angioedema drug, a supplement that worsened Parkinson's, HPV vaccination in pregnancy, and benzodiazepines in pregnancy
A ranked ten-minute triage of five papers that entered PubMed between October 6 and 13, 2026: an optogenetic gene therapy that restored light sensitivity in seven of ten people blind from retinitis pigmentosa, an oral hereditary angioedema drug, a randomized nicotinamide riboside trial that worsened Parkinson's scores, and two large pregnancy-safety analyses on HPV vaccination and benzodiazepines.
This issue covers the papers that entered PubMed between October 6 and October 13, 2026, dated by each record's PubMed entry date. The five run from a first-in-human eye-gene therapy to two large pregnancy-safety analyses, with an oral angioedema drug and a Parkinson's supplement trial in between.
Every paper here is days old, so the citation signal is still nearly empty. Crossref and OpenAlex return 0 or 1 cited-by works for each of the five, and the table below carries the individual counts so you can re-rank the list yourself. The order runs on journal tier first, then on randomized design, sample size, endpoint strength, and how directly a result changes a decision.
The fifth slot goes to the week's strongest NIH-funded paper. The benzodiazepine-pregnancy analysis was funded by the National Institute of Child Health and Human Development.
At a glance
| Rank | Paper | Journal and tier | Design and sample | Primary result | Early cited-by signal |
|---|---|---|---|---|---|
| 1 | Optogenetic Therapy for Restoring Aspects of Visual Function 1 | The New England Journal of Medicine; very high impact tier | Open-label phase 1/2 dose-escalation study, no control group; 10 participants blind from advanced retinitis pigmentosa | Light sensitivity rose in 7 of 10 participants, by a factor of 2.0 to 62.3; 6 crossed the study's 0.6-log-unit threshold for clinical meaning. The primary outcome was safety | 1 2 |
| 2 | Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-3) 3 | The Lancet; very high impact tier | Phase 3, double-blind, placebo-controlled crossover; 134 randomized, 88 with paired treated attacks in the primary analysis | Median time to onset of symptom relief 1.28 h with deucrictibant (95% CI 1.05–1.52) against more than 12 h with placebo (95% CI 5.82 to >12); P<0.0001 | 1 4 |
| 3 | Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease (NOPARK) 5 | JAMA; very high impact tier | Phase 3, randomized, double-blind, placebo-controlled; 410 randomized, 393 analyzed over 52 weeks | MDS-UPDRS total score rose 2.45 points with nicotinamide riboside against a fall of 0.27 with placebo; adjusted mean difference 2.72 points favoring placebo (95% CI 0.47–4.98; P=.02) | 0 6 |
| 4 | Quadrivalent human papillomavirus vaccination before pregnancy and pregnancy outcomes 7 | BMJ; very high impact tier | Nationwide, population-based matched case-control study, Sweden 2006–2023; 624,713 singleton births, 92,620 (14.8%) vaccinated | Adjusted odds ratio 0.95 for preterm birth (95% CI 0.91–0.99), 0.85 for very preterm birth (0.75–0.97), 0.92 for severe small-for-gestational-age (0.87–0.97) | 0 8 |
| 5 | Benzodiazepine Use Early in Pregnancy and Risk for Congenital Malformations 9 | Annals of Internal Medicine; high impact tier, general medicine; NIH-funded | Population-based cohort in US Medicaid (2000–2018) and MarketScan (2003–2020); 4,229,155 pregnancies, 79,118 with first-trimester exposure | Pooled adjusted relative risk for any major congenital malformation 0.99 (95% CI 0.96–1.03), inside the prespecified 1.3 threshold for clinical significance | 0 10 |
1. Optogenetic gene therapy lifts light sensitivity in seven of ten people blind from retinitis pigmentosa
Journal and impact tier: The New England Journal of Medicine, very high impact tier; volume 395, issue 14. PubMed entered the paper on October 7, 2026, under PMID 42842903. 1
Author and affiliation: First author José-Alain Sahel is in the Department of Ophthalmology at the University of Pittsburgh School of Medicine and at the Institut de la Vision, Sorbonne Université, in Paris. The closing author, Botond Roska, is at the Institute of Molecular and Clinical Ophthalmology Basel. 1
Design, setting, and sample: PIONEER is an open-label dose-escalation study. Ten participants with blindness from advanced retinitis pigmentosa received one intravitreal injection of an adeno-associated viral vector carrying ChrimsonR, a red-shifted channelrhodopsin, into the worse-seeing eye. The registry lists 10 enrolled participants at three sites, sponsored by GenSight Biologics, and the study is still active. 11
Primary endpoint and quantitative result: The primary outcome was safety. Nine of the ten participants had 34 ocular adverse events: 23 mild, 10 moderate, and one severe. 1 In the secondary outcome, light sensitivity measured by full-field stimulus threshold testing rose in 7 of the 10 participants, by a factor of 2.0 to 62.3, and 6 participants crossed the study's threshold for a clinically meaningful gain, set at a decrease of at least 0.6 log units. 1
Why it matters: The participants were blind from a degenerative retinal disease with no treatment at that stage. The intervention is a single injection that makes surviving retinal ganglion cells respond to light, and the trial measured that response with a threshold test rather than a patient-reported outcome. An editorial, "Optogenetics in Sight," ran in the same issue. 12
Limitation and evidence boundary: The design is open-label with no control group and ten participants, so the light-sensitivity change is an observation in a small cohort rather than an efficacy estimate. The 0.6-log-unit threshold for a meaningful improvement came from published literature and was not prespecified in the protocol. The one severe event was a transient occlusion of the central retinal artery immediately after injection, which resolved within minutes of treatment with iopidine. 1
Funding or disclosure: Funded by GenSight Biologics, the developer of the vector; registered as PIONEER, NCT03326336. 11
2. An oral bradykinin blocker relieves hereditary angioedema attacks in about an hour
Journal and impact tier: The Lancet, very high impact tier. PubMed entered the paper on October 8, 2026, under PMID 42849489. 3
Author and affiliation: First and corresponding author Marc A. Riedl is in the Division of Allergy and Immunology at the University of California, San Diego. The closing author, Danny M. Cohn, is in the Department of Vascular Medicine at Amsterdam University Medical Center. 3
Design, setting, and sample: RAPIDe-3 is a phase 3, double-blind, placebo-controlled crossover trial at 59 sites in 24 countries. 134 adolescents and adults with hereditary angioedema were randomly assigned to treat two attacks with a 20 mg oral deucrictibant capsule or matching placebo. The primary efficacy analysis covered the 88 participants who treated an attack on each treatment arm. The registry lists the completed phase 3 study, sponsored by Pharvaris Netherlands. 13
Primary endpoint and quantitative result: The primary endpoint was time to onset of symptom relief, defined as a Patient Global Impression of Change rating of at least "a little better." Median onset was 1.28 hours with deucrictibant (95% CI 1.05 to 1.52) against more than 12 hours with placebo (95% CI 5.82 to >12); P<0.0001. Fatigue was the only adverse event reported more than once within three days of treatment. No treatment-related adverse event was assessed as severe or serious, and none led to discontinuation. 3
Why it matters: Attacks of hereditary angioedema are currently treated with subcutaneous or intravenous injectables, which patients must carry and administer mid-attack. Deucrictibant would be the first oral bradykinin B2 receptor antagonist for on-demand use, which changes what a patient can keep in a pocket rather than a refrigerator. A companion Lancet comment makes the same case. 14
Limitation and evidence boundary: The primary comparison rests on 88 participants with paired treated attacks, so the effect size is large and the sample small. Onset of relief is the endpoint the trial powered; time to complete attack resolution is not reported in the abstract. Ten of the 134 participants were adolescents, so the result speaks mostly to adults, with a median age of 38 in the primary analysis. 3
Funding or disclosure: Funded by Pharvaris, the developer of deucrictibant; registered as RAPIDe-3, NCT06343779. 13
3. Nicotinamide riboside worsened scores in early Parkinson's disease over a year
Journal and impact tier: JAMA, very high impact tier. PubMed entered the paper on October 8, 2026, under PMID 42848371. 5
Author and affiliation: First author Brage Brakedal is at the Neuro-SysMed Center for Clinical Treatment Research, Department of Neurology, Haukeland University Hospital, and the Department of Clinical Medicine, University of Bergen. The closing author, Charalampos Tzoulis, is at the same two institutions. 5
Design, setting, and sample: NOPARK randomized patients with Parkinson's disease diagnosed within the previous two years to oral nicotinamide riboside 500 mg twice daily or matching placebo for 52 weeks. Of 537 people screened, 410 were randomly assigned and 393 entered the primary analysis; the mean age was 65.6 years and 133 (34%) were women. The registry lists the completed study, sponsored by Haukeland University Hospital. 15
Primary endpoint and quantitative result: On the Movement Disorder Society Unified Parkinson's Disease Rating Scale (parts I–III, range 0–236, higher is worse), the total score rose by 2.45 points with nicotinamide riboside (95% CI 0.80 to 4.10) and fell by 0.27 points with placebo (95% CI −1.95 to 1.40), an adjusted mean difference of 2.72 points favoring placebo (95% CI 0.47 to 4.98; P=.02). Nonmotor symptom burden also rose more with the supplement, by an adjusted 4.22 points (95% CI 1.07 to 7.37; P=.009). Serious adverse events were reported in 8.3% of the supplement group and 14.1% of the placebo group. 5
Why it matters: Nicotinamide riboside is sold widely as an NAD+ supplement, and this is a randomized test of it at 500 mg twice daily for a year in people with newly diagnosed Parkinson's disease. Both the primary scale and the non-motor scale moved the wrong way on the supplement. JAMA published a separate research summary for patients alongside it. 16
Limitation and evidence boundary: The between-group difference of 2.72 points sits below the 5.2-point change the trial itself defines as a clinically important worsening, so the finding is a direction of effect with a modest magnitude. The trial ran 52 weeks, which is short for a disease that progresses over decades, and it enrolled people within two years of diagnosis, so it says nothing about later disease. 5
Funding or disclosure: Several authors, including the closing author, disclose patents on nicotinamide riboside as a treatment for Parkinson's disease, licensed to Niagen Bioscience. The trial was sponsored by Haukeland University Hospital; the abstract names no separate commercial funder. 15
4. HPV vaccination before pregnancy tracks with lower odds of adverse birth outcomes
Journal and impact tier: BMJ, very high impact tier; volume 395. PubMed entered the paper on October 7, 2026, under PMID 42843853. 7
Author and affiliation: First author Zhongsong Zhang is in the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet, Stockholm. The closing author, Jiayao Lei, is in the same department and at the Center for Cervical Cancer Elimination at Karolinska Institutet. 7
Design, setting, and sample: Nationwide, population-based matched case-control study of Swedish registers from January 1, 2006, to December 31, 2023. 624,713 singleton births among nulliparous women aged 16 to 35 entered the analysis, and 92,620 (14.8%) of the women had received quadrivalent HPV vaccination before pregnancy. Conditional logistic regression produced odds ratios adjusted for confounders. 7
Main outcome and quantitative result: Adjusted odds ratios sat below 1.0 for every outcome the authors examined. Preterm birth before 37 weeks came in at 0.95 (95% CI 0.91 to 0.99), very preterm birth at 28 to 31 weeks at 0.85 (0.75 to 0.97), spontaneous preterm birth at 0.95 (0.91 to 0.99), preterm prelabour rupture of membranes at 0.93 (0.87 to 1.00), and severe small-for-gestational-age below the third centile at 0.92 (0.87 to 0.97). Reductions were larger among women vaccinated at younger ages. The authors report no separate estimates for stillbirth and neonatal mortality in the abstract. 7
Why it matters: Questions about vaccination in the months before conception still reach obstetric clinics. A national register with more than 600,000 births gives a counsellor a population-scale figure, and it puts the direction of the association on the reassuring side. 7
Limitation and evidence boundary: The study is observational, so it can adjust for the confounders the registers capture and nothing else; vaccinated and unvaccinated women differ in age, health contact, and education. The effect sizes are small, which makes the result better evidence against a large increase in risk than evidence of protection. The findings cover the quadrivalent vaccine and the Swedish population. 7
Funding or disclosure: Supported by the Swedish Cancer Society, the Swedish Research Council, the Swedish Research Council for Health, Working Life and Welfare, Karolinska Institutet, Region Stockholm, and Swedish governmental funding of clinical research. 7
5. Benzodiazepines in early pregnancy showed no malformation signal across 4.2 million pregnancies
Journal and impact tier: Annals of Internal Medicine, high impact tier in general medicine. PubMed entered the paper on October 13, 2026, under PMID 42863122. 9
Author and affiliation: First author Kelly Fung is in the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, in Boston. The closing author, Krista F. Huybrechts, is in the same division and in the Department of Epidemiology at the Harvard T.H. Chan School of Public Health. 9
Design, setting, and sample: Population-based cohort study drawing on US Medicaid claims from 2000 to 2018 and the Merative MarketScan database from 2003 to 2020. Of 2,478,434 publicly insured pregnancies, 51,339 (2.1%) had a first-trimester benzodiazepine fill; of 1,750,721 commercially insured pregnancies, 27,779 (1.6%) did. Relative risks came from propensity-score fine stratification weighting. 9
Main outcome and quantitative result: The adjusted absolute risk of any major congenital malformation was 4.0% in exposed against 4.1% in unexposed pregnancies in Medicaid, and 4.9% against 4.8% in MarketScan. The pooled adjusted relative risk was 0.99 (95% CI 0.96 to 1.03), well inside the threshold of 1.3 the authors set in advance for clinical significance. Analyses by individual benzodiazepine gave similar results, and no dose-response relationship appeared. Elevated risks for specific organ malformations appeared in some analyses of benzodiazepines taken alongside other psychoactive medications, without a consistent pattern. 9
Why it matters: The question arrives in clinic constantly: a patient taking a benzodiazepine for anxiety or insomnia who is planning a pregnancy or has just conceived. The authors describe the existing data on malformation risk as conflicting. Two insurance databases covering 4.2 million pregnancies, with a significance threshold fixed in advance, give the counselling a population-scale estimate. 9
Limitation and evidence boundary: The design is observational, and the authors name exposure and outcome misclassification as a limit, along with the restriction to malformations visible at birth. Claims data record a filled prescription rather than a dose taken. The finding covers first-trimester exposure and major malformations at birth, so it says nothing about longer-term neurodevelopment. 9
Funding or disclosure: The primary funding source is the National Institute of Child Health and Human Development. 9
What to open first
- Retinal gene therapy: Open PIONEER if your question is what a single intravitreal ChrimsonR injection did to light sensitivity in ten people, and what the safety record looks like at that stage. 1
- Hereditary angioedema: Open RAPIDe-3 if your question is whether an oral capsule matches the speed of injected on-demand therapy, and how the crossover design handled the paired-attack comparison. 3
- Patients asking about NAD+ supplements: Open NOPARK if your question is what the largest randomized test of nicotinamide riboside found on the MDS-UPDRS, and which secondary measures moved with it. 5
- Preconception counselling on vaccination: Open the Swedish register study if your question is what quadrivalent HPV vaccination before pregnancy did to preterm birth odds across 624,713 births. 7
- Prescribing a benzodiazepine in early pregnancy: Open the Medicaid and MarketScan cohort if your question is what 4.2 million pregnancies say about major malformations after a first-trimester fill. 9
References
- 1Optogenetic Therapy for Restoring Aspects of Visual Function
pubmed.ncbi.nlm.nih.gov
- 2OpenAlex record for the PIONEER report
openalex.org
- 3Oral deucrictibant for on-demand treatment of hereditary angioedema attacks
pubmed.ncbi.nlm.nih.gov
- 4OpenAlex record for the RAPIDe-3 report
openalex.org
- 5Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease
pubmed.ncbi.nlm.nih.gov
- 6OpenAlex record for the NOPARK report
openalex.org
- 7Quadrivalent human papillomavirus vaccination before pregnancy and pregnancy outcomes
pubmed.ncbi.nlm.nih.gov
- 8OpenAlex record for the HPV vaccination study
openalex.org
- 9Benzodiazepine Use Early in Pregnancy and Risk for Congenital Malformations
pubmed.ncbi.nlm.nih.gov
- 10
- 11
- 12Optogenetics in Sight
pubmed.ncbi.nlm.nih.gov
- 13
- 14Deucrictibant: a novel oral on-demand treatment for hereditary angioedema
pubmed.ncbi.nlm.nih.gov
- 15
- 16Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: Research Summary
pubmed.ncbi.nlm.nih.gov
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.